FDA Approves New Treatment for Allergic Skin Conditions in Dogs

U.S. Food and Drug Administration sent this bulletin at 09/19/2024 02:02 PM EDT

If your email program has trouble displaying this email, view as a webpage.
US Food and Drug Administration

FDA Approves New Treatment for Allergic Skin Conditions in Dogs

Today, the U.S. Food and Drug Administration approved Zenrelia (ilunocitinib tablets), a new animal drug used to control pruritus (itching) associated with allergic dermatitis and to control atopic dermatitis (environmental allergies) in dogs at least 1 year of age.

Zenrelia is an immunosuppressant that is administered orally, once daily, with or without food. The active ingredient, ilunocitinib, is a non-selective Janus kinase (JAK) inhibitor and is the second JAK inhibitor the FDA has approved for this indication.

Read More Button


You are subscribed to updates from FDA's Center for Veterinary Medicine.